Veralipride

Veralipride

Clinical data
Routes of administration	Oral
ATC code	N05AL06 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name N-[(1-Allylpyrrolidin-2-yl)methyl]-5-(aminosulfonyl)-2,3-dimethoxybenzamide
CAS Number	66644-81-3 Y
PubChem CID	47979
ChemSpider	43638 N
UNII	S7064109UD
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C17H25N3O5S
Molar mass	383.4625 g/mol
3D model (JSmol)	Interactive image
SMILES COC1=CC(=CC(=C1OC)C(=O)NCC2CCCN2CC=C)S(=O)(=O)N
InChI InChI=1S/C17H25N3O5S/c1-4-7-20-8-5-6-12(20)11-19-17(21)14-9-13(26(18,22)23)10-15(24-2)16(14)25-3/h4,9-10,12H,1,5-8,11H2,2-3H3,(H,19,21)(H2,18,22,23) N Key:RYJXBGGBZJGVQF-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Veralipride (Agreal, Agradil) is a benzamide neuroleptic medicine indicated in the treatment of vasomotor symptoms associated with the menopause. It was first authorised for use in 1979. Veralipride has never gained approval in the United States.

On September 2006, it was withdrawn from the Spanish market. As a result, the European Commission referred the matter to the European Medicines Agency (EMA). On July 2007, the EMA recommended the withdrawal of marketing authorisations for veralipride.

See also

• Typical antipsychotic
• Benzamide